Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.65 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.65 |
| ▸ | OSBP | P22059 | 1/20 | 0.65 |
| ▸ | RORC | P51449 | 1/20 | 0.65 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.65 |
| ▸ | POLA1 | P09884 | 1/20 | 0.61 |
| ▸ | GRIN1 | Q05586 | 12/20 | 0.60 |
| ▸ | GRIN2B | Q13224 | 12/20 | 0.60 |
| ▸ | GRIN2A | Q12879 | 10/20 | 0.59 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22194040 | 1.00 | USP2 (0.65) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL2637585 | 0.91 | USP2 (0.67) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL2221515 | 0.91 | USP2 (0.67) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL6060845 | 0.90 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL27963051 | 0.90 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL27963054 | 0.90 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL2638134 | 0.90 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL27975861 | 0.90 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL8426935 | 0.90 | USP2 (0.67) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL18631920 | 0.88 | USP2 (0.63) | USP2CYP46A1LMNAABCB1OSBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4701639-A1 | MOLECULES TARGETING INFECTED TISSUES AND METHODS OF USE THEREOF | University of Tartu (EE) | 2026-03-04 | — | — | EP | disclosed |
| WO-2024249553-A1 | MOLECULES TARGETING INFECTED TISSUES AND METHODS OF USE THEREOF | UNIVERSITY OF TARTU (EE) | 2024-12-05 | — | — | WO | disclosed |
| EP-4429633-A1 | NANOPARTICULATE FORMULATION | Newimmune II, LLC (US) | 2024-09-18 | — | — | EP | disclosed |
| EP-4247493-A1 | METHODS AND COMPOSITIONS COMPRISING CATIONIC LIPIDS FOR IMMUNOTHERAPY BY DIRECT TUMOR INJECTION | PDS Biotechnology Corporation (US) | 2023-09-27 | — | — | EP | disclosed |
| WO-2023062353-A1 | NANOPARTICULATE FORMULATION | NEWIMMUNE II, LLC (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2022109391-A1 | METHODS AND COMPOSITIONS COMPRISING CATIONIC LIPIDS FOR IMMUNOTHERAPY BY DIRECT TUMOR INJECTION | PDS BIOTECHNOLOGY CORPORATION (US) | 2022-05-27 | — | — | WO | disclosed |
| US-10709664-B2 | Nanolipogel comprising a polymeric matrix and a lipid shell | YALE UNIVERSITY (US) | 2020-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10709664-B2 | Nanolipogel comprising a polymeric matrix and a lipid shell | LIPA, CD44, ABCB4 | USP2 1111/4885CYP46A1 464/4885LMNA 4214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.